1. Home
  2. IMNM vs CLM Comparison

IMNM vs CLM Comparison

Compare IMNM & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$25.64

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.46

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
CLM
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
IMNM
CLM
Price
$25.64
$7.46
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$32.80
N/A
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.67
$6.92
52 Week High
$27.65
$8.53

Technical Indicators

Market Signals
Indicator
IMNM
CLM
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
IMNM
CLM

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.

Share on Social Networks: